# US 2022/0033846 A1 · App modification via base editing using the crispr/cas9 system

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033846 A1
- Document ID: US20220033846A1
- Status: Published application
- Kind: A1
- Application number: 17/309,808
- Filed: 2019-12-20
- Published: 2022-02-03
- Earliest claimed: 2018-12-21
- Inventors: Jacques P. TREMBLAY; Joël ROUSSEAU; Antoine GUYON
- Web page: https://patentgrep.com/patent/US20220033846A1

## CPC

- C12N 15/10: Processes for the isolation, preparation or purification of DNA or RNA (chemical preparation of DNA or RNA C07H21/00; preparation of non-structural polynucleotides from microorganisms or with enzymes C12P19/34)
- C12N 15/85: for animal cells
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07K 14/4711: {Alzheimer's disease; Amyloid plaque core protein}
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12Y 305/04004: Adenosine deaminase (3.5.4.4)
- C12Y 305/04005: Cytidine deaminase (3.5.4.5)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 38/46: Hydrolases (3)
- C07K 2319/80: containing a DNA binding domain, e.g. Lacl or Tet-repressor
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2740/16043: viral genome or elements thereof as genetic vector
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

Methods and products (e.g., guide RNAs or pegRNA and recombinant proteins) are described for decreasing amyloidogenic Aβ peptide levels produced by a cell, or the aggregation of the Aβ peptide, as well as uses of such methods and products, for example for the treatment of Alzheimer's disease and/or age-related cognitive decline in a subject in need thereof.

## Claims

### Claim 1

A method of decreasing Amyloid Precursor Protein (APP) processing into amyloidogenic Aβ peptide by a cell or the aggregation of the Aβ peptide, comprising providing said cell with:
a. a1) at least one guide RNA comprising a seed region of at least 18 consecutive nucleotides of a target sequence in an endogenous APP-encoding polynucleotide sequence present in said cell, wherein the target sequence of the guide RNA guide sequence is contiguous to a protospacer adjacent motif (PAM) in the endogenous APP gene polynucleotide sequence and wherein said PAM is recognized by a ribonucleoprotein complex comprising a Cas9 nickase; or
a2) a vector comprising a nucleic acid sequence corresponding to the guide RNA for expressing the guide RNA; and
b. b1) a Cas nickase-deaminase fusion protein comprising (i) a Cas nickase polypeptide domain and (ii) a cytidine deaminase polypeptide domain or an adenosine deaminase polypeptide domain; or
b2) a vector comprising a nucleic acid sequence encoding the Cas nickase-deaminase fusion protein, for expression of the Cas nickase-deaminase fusion protein; and
wherein at least one modification is introduced into the target sequence of the APP-encoding polynucleotide, wherein the at least one modification comprises modification of a cytidine into a thymidine or an adenosine into an inosine, and wherein the at least one modification decreases the processing of APP into amyloidogenic Aβ peptide by the cell or the aggregation of the Aβ peptide; and wherein if the APP-encoding nucleotide is mRNA and the at least one modification comprises deamination of an adenosine into an inosine, the gRNA further comprises a cytidine mismatch with the adenosine to be deaminated to an inosine in the target sequence.

### Claim at position 2

2-4. (canceled)

### Claim 5 (depends on 1)

The method of claim 1, wherein the at least one modification is located in intron 15, exon 16, intron 16, exon 17 and/or intron 17 of the APP-encoding polynucleotide sequence.

### Claim 6 (depends on 1)

The method of claim 1, wherein said at least one modification results in at least one amino acid substitution in the region defined by amino acid positions 656 to 688 in the APP protein, wherein said amino acid positions are with respect to the APP protein sequence as set forth in SEQ ID NO: 2.

### Claim 7 (depends on 6)

The method of claim 6, wherein said at least one amino acid substitution corresponds to at least one substitution at amino acid position 670, 671, 673, 678, 682, 684, 692, 693, 694, 704, 711, 712, 713, 714, 715 and/or 684 of the APP protein.

### Claim at position 6

8-11. (canceled)

### Claim 12 (depends on 5)

The method of claim 5, wherein said at least one modification corrects a mutation associated with an increased risk of developing Alzheimer's disease present in said endogenous APP polynucleotide gene sequence present in said cell.

### Claim 13 (depends on 5)

The method of claim 5, wherein said at least one modification results in a mutation which reduces risk of developing Alzheimer's disease by reducing the formation or the aggregation of Amyloidogenic peptides.

### Claim at position 9

14-26. (canceled)

### Claim 27 (depends on 1)

A guide RNA as defined in claim 1.

### Claim 28 (depends on 27)

An isolated nucleic acid comprising a nucleotide sequence corresponding to the guide RNA of claim 27 for expressing the guide RNA.

### Claim 29

(canceled)

### Claim 30 (depends on 28)

A vector comprising the isolated nucleic acid of claim 28.

### Claim at position 14

31-50. (canceled)

### Claim 51

A method of decreasing Amyloid Precursor Protein (APP) processing into amyloidogenic Aβ peptide by a cell or the aggregation of the Aβ peptide, comprising providing said cell with:
a. a1) at least one pegRNA comprising a seed region of at least 18 consecutive nucleotides of a target sequence in an endogenous APP-encoding polynucleotide sequence present in said cell, wherein the target sequence of the pegRNA guide sequence is contiguous to a protospacer adjacent motif (PAM) in the endogenous APP gene polynucleotide sequence and wherein said PAM is recognized by a ribonucleoprotein complex comprising a Cas9 nickase; or
a2) a vector comprising a nucleic acid sequence corresponding to the pegRNA for expressing the pegRNA; and
b. b1) a Cas nickase-reverse transcriptase fusion protein comprising (i) a Cas nickase polypeptide domain and (ii) a reverse transcriptase polypeptide domain; or
b2) a vector comprising a nucleic acid sequence encoding the Cas nickase-reverse transcriptase fusion protein, for expression of the Cas nickase-reverse transcriptase fusion protein; and
wherein at least one modification is introduced into the target sequence of the APP-encoding polynucleotide, wherein the at least one modification decreases the processing of APP into amyloidogenic Aβ peptide by the cell or the aggregation of the Aβ peptide.

### Claim at position 16

52-54. (canceled)

### Claim 55 (depends on 51)

The method of claim 51, wherein the at least one modification is located in intron 15, exon 16, intron 16, exon 17 and/or intron 17 of the APP-encoding polynucleotide sequence.

### Claim 56 (depends on 51)

The method of claim 51, wherein said at least one modification results in at least one amino acid substitution in the region defined by amino acid positions 656 to 688 in the APP protein, wherein said amino acid positions are with respect to the APP protein sequence as set forth in SEQ ID NO: 2.

### Claim 57 (depends on 56)

The method of claim 56, wherein said at least one amino acid substitution corresponds to at least one substitution at amino acid position 670, 671, 673, 678, 682, 684, 692, 693, 694, 704, 711, 712, 713, 714, 715 and/or 684 of the APP protein.

### Claim at position 20

58-61. (canceled)

### Claim 62 (depends on 55)

The method of claim 55, wherein said at least one modification corrects a mutation associated with an increased risk of developing Alzheimer's disease present in said endogenous APP polynucleotide gene sequence present in said cell.

### Claim 63 (depends on 55)

The method of claim 55, wherein said at least one modification results in a mutation which reduces risk of developing Alzheimer's disease by reducing the formation or the aggregation of Amyloidogenic peptides.

### Claim at position 23

64-76. (canceled)

### Claim 77 (depends on 51)

A guide RNA as defined in claim 51.

### Claim 78 (depends on 77)

An isolated nucleic acid comprising a nucleotide sequence corresponding to the guide RNA of claim 77 for expressing the guide RNA.

### Claim 79

(canceled)

### Claim 80 (depends on 78)

A vector comprising the isolated nucleic acid of claim 78.

### Claim at position 28

81-100. (canceled)

### Claim 101 (depends on 7)

The method of claim 7, wherein said at least one amino acid substitution corresponds to at least one substitution at amino acid position 673 and/or 684 of the APP protein.

### Claim 101 (depends on 57)

The method of claim 57, wherein said at least one amino acid substitution corresponds to at least one substitution at amino acid position 673 and/or 684 of the APP protein.
